Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bookman, M. A.
Right arrow Articles by Fields, S. Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bookman, M. A.
Right arrow Articles by Fields, S. Z.

Journal of Clinical Oncology, Vol 16, 3345-3352, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

MA Bookman, H Malmstrom, G Bolis, A Gordon, A Lissoni, JB Krebs and SZ Fields
Fox Chase Cancer Center, Department of Medical Oncology, Philadelphia, PA 19111, USA. ma_bookman@fccc.edu

PURPOSE: Topotecan, a topoisomerase I inhibitor, was evaluated in a multicenter, phase II study of women with epithelial ovarian carcinoma who relapsed after one or two prior regimens that included platinum and paclitaxel. PATIENTS AND METHODS: Topotecan 1.5 mg/m2 daily was administered as a 30-minute infusion for 5 consecutive days on a 21-day cycle. Eligibility criteria included bidimensionally measurable disease, Eastern Cooperative Oncology Group performance status of 2 or less, and adequate bone marrow, liver, and renal function. Efficacy was assessed by independent radiologic review. RESULTS: One hundred thirty- nine patients were treated; 81% were platinum resistant. Sixty-two patients had received one prior regimen and 77 patients had received two prior regimens. Nine patients were not assessable for response; however, all patients were included in the response analysis. The overall response rate was 13.7%; 12.4% in platinum-resistant and 19.2% in platinum-sensitive patients. Stable disease lasted at least 8 weeks in 27.3% of the patients. The median duration of response and time to progression were 18.1 and 12.1 weeks, respectively. The median survival was 47.0 weeks. Grade 4 neutropenia occurred in 82% of the patients (34% of the courses) and thrombocytopenia in 30% of the patients (9% of the courses). Infectious complications occurred in 6% of the courses. Nonhematologic toxicities were mild. There were no drug-related toxic deaths. CONCLUSION: As a single agent, topotecan has modest activity in women with advanced epithelial ovarian carcinoma who have progressed or not responded after one or two prior regimens with platinum and paclitaxel. Further investigation of combination regimens is indicated in the primary therapy for ovarian cancer based on the mechanism of action and tolerability.


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
M. K. B. Parmar, Friederike. M.-S. Barthel, M. Sydes, R. Langley, R. Kaplan, E. Eisenhauer, M. Brady, N. James, M. A. Bookman, A.-M. Swart, et al.
Speeding up the Evaluation of New Agents in Cancer
J Natl Cancer Inst, September 3, 2008; 100(17): 1204 - 1214.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
H. W Tuffaha, I. M Treish, and L. Zaru
The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting
Journal of Oncology Pharmacy Practice, September 1, 2008; 14(3): 131 - 138.
[Abstract] [PDF]

Home page
 JCOHome page
J. Sehouli, D. Stengel, G. Oskay-Oezcelik, A. G. Zeimet, H. Sommer, P. Klare, M. Stauch, A. Paulenz, O. Camara, E. Keil, et al.
Nonplatinum Topotecan Combinations Versus Topotecan Alone for Recurrent Ovarian Cancer: Results of a Phase III Study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
J. Clin. Oncol., July 1, 2008; 26(19): 3176 - 3182.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
U Seifart, T Fink, C Schade-Brittinger, K Hans, C Mueller, G Koschel, H Schroeder, R Lorenz, J Dethling, and M Wolf
Randomised phase II study comparing topotecan/carboplatin administration for 5 versus 3 days in the treatment of extensive-stage small-cell lung cancer
Ann. Onc., January 1, 2007; 18(1): 104 - 109.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. Pectasides, E. Pectasides, and T. Economopoulos
Fallopian Tube Carcinoma: A Review
Oncologist, September 1, 2006; 11(8): 902 - 912.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. J. Smith, J. Khatcheressian, G. H. Lyman, H. Ozer, J. O. Armitage, L. Balducci, C. L. Bennett, S. B. Cantor, J. Crawford, S. J. Cross, et al.
2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline
J. Clin. Oncol., July 1, 2006; 24(19): 3187 - 3205.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. K. Armstrong, D. Spriggs, J. Levin, R. Poulin, and S. Lane
Hematologic Safety and Tolerability of Topotecan in Recurrent Ovarian Cancer and Small Cell Lung Cancer: An Integrated Analysis
Oncologist, October 1, 2005; 10(9): 686 - 694.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Campos, O. Hamid, M. V. Seiden, A. Oza, M. Plante, R. K. Potkul, P. F. Lenehan, E. P. Kaldjian, M. L. Varterasian, C. Jordan, et al.
Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer
J. Clin. Oncol., August 20, 2005; 23(24): 5597 - 5604.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Mirchandani, H. Hochster, A. Hamilton, L. Liebes, H. Yee, J. P. Curtin, S. Lee, J. Sorich, C. Dellenbaugh, and F. M. Muggia
Phase I Study of Combined Pegylated Liposomal Doxorubicin with Protracted Daily Topotecan for Ovarian Cancer
Clin. Cancer Res., August 15, 2005; 11(16): 5912 - 5919.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Sessa, F. De Braud, A. Perotti, J. Bauer, G. Curigliano, C. Noberasco, F. Zanaboni, L. Gianni, S. Marsoni, J. Jimeno, et al.
Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails
J. Clin. Oncol., March 20, 2005; 23(9): 1867 - 1874.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. G. Rose
Pegylated Liposomal Doxorubicin: Optimizing the Dosing Schedule in Ovarian Cancer
Oncologist, March 1, 2005; 10(3): 205 - 214.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. A. Cannistra
Cancer of the Ovary
N. Engl. J. Med., December 9, 2004; 351(24): 2519 - 2529.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. J. Herzog
Recurrent Ovarian Cancer: How Important Is It to Treat to Disease Progression?
Clin. Cancer Res., November 15, 2004; 10(22): 7439 - 7449.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. C. Zamboni, L. L. Jung, M. J. Egorin, D. M. Potter, D. M. Friedland, C. P. Belani, S. S. Agarwala, M. M. W. Wong, M. Fakih, D. L. Trump, et al.
Phase I and Pharmacologic Study of Intermittently Administered 9-Nitrocamptothecin in Patients with Advanced Solid Tumors
Clin. Cancer Res., August 1, 2004; 10(15): 5058 - 5064.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. K. Armstrong
Topotecan Dosing Guidelines in Ovarian Cancer: Reduction and Management of Hematologic Toxicity
Oncologist, February 1, 2004; 9(1): 33 - 42.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. T. Wong and A. Berkenblit
The Role of Topotecan in the Treatment of Brain Metastases
Oncologist, February 1, 2004; 9(1): 68 - 79.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
W. ten Bokkel Huinink, S. R. Lane, and G. A. Ross
Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma
Ann. Onc., January 1, 2004; 15(1): 100 - 103.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Beran, S. O'Brien, D. A. Thomas, H. T. Tran, J. E. Cortes-Franco, F. Giles, E. Estey, and H. M. Kantarjian
Phase I Study of Oral Topotecan in Hematological Malignancies
Clin. Cancer Res., September 15, 2003; 9(11): 4084 - 4091.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Aravantinos, D. Bafaloukos, G. Fountzilas, C. Christodoulou, C. Papadimitriou, N. Pavlidis, H. P. Kalofonos, H. Gogas, P. Kosmidis, and M. A. Dimopoulos
Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer
Ann. Onc., July 1, 2003; 14(7): 1094 - 1099.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. P. Braybrooke, E. Boven, N. P. Bates, R. Ruijter, N. Dobbs, P. D. Cheverton, H. M. Pinedo, and D. C. Talbot
Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f ), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies
Ann. Onc., June 1, 2003; 14(6): 913 - 921.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Bookman
Developmental Chemotherapy and Management of Recurrent Ovarian Cancer
J. Clin. Oncol., May 15, 2003; 21(90100): 149s - 167.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. K. Armstrong
Novel Therapies in Ovarian Cancer Management: An Update on the Role of Topotecan
Oncologist, October 1, 2002; 7(90005): 1 - 2.
[Full Text] [PDF]

Home page
 The OncologistHome page
T. J. Herzog
Update on the Role of Topotecan in the Treatment of Recurrent Ovarian Cancer
Oncologist, October 1, 2002; 7(90005): 3 - 10.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. K. Armstrong
Relapsed Ovarian Cancer: Challenges and Management Strategies for a Chronic Disease
Oncologist, October 1, 2002; 7(90005): 20 - 28.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. Morris and A. Munkarah
Alternate Dosing Schedules for Topotecan in the Treatment of Recurrent Ovarian Cancer
Oncologist, October 1, 2002; 7(90005): 29 - 35.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. L. Coleman
Emerging Role of Topotecan in Front-Line Treatment of Carcinoma of the Ovary
Oncologist, October 1, 2002; 7(90005): 46 - 55.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. K. Rowinsky
Weekly Topotecan: An Alternative to Topotecan's Standard Daily x 5 Schedule?
Oncologist, August 1, 2002; 7(4): 324 - 330.
[Abstract] [Full Text] [PDF]

Home page
 Reproductive SciencesHome page
A. Hasenburg, D.-C. Fischer, X.-W. Tong, A. Rojas-Martinez, R. H. Kaufman, I. Ramzy, P. Kohlberger, M. Orlowska-Volk, E. Aguilar-Cordova, and D. G. Kieback
Adenovirus-Mediated Thymidine Kinase Gene Therapy for Recurrent Ovarian Cancer: Expression of Coxsackie-Adenovirus Receptor and Integrins {alpha}v{beta}3 and {alpha}v{beta}5
Reproductive Sciences, May 1, 2002; 9(3): 174 - 180.
[Abstract] [PDF]

Home page
 JCOHome page
R. F. Ozols
Recurrent Ovarian Cancer: Evidence-Based Treatment
J. Clin. Oncol., March 1, 2002; 20(5): 1161 - 1163.
[Full Text] [PDF]

Home page
 Ann OncolHome page
G. Tortora, F. Ciardiello, V. Damiano, M. De Laurentiis, E. Matano, S. Pepe, M. Pensabene, G. Catalano, S. De Placido, and A. R. Bianco
Preclinical and phase I study of oxaliplatin and topotecan in combination in human cancer
Ann. Onc., March 1, 2002; 13(3): 392 - 398.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
V. Dieras, P. Bougnoux, T. Petit, P. Chollet, P. Beuzeboc, C. Borel, F. Husseini, A. Goupil, P. Kerbrat, J. L. Misset, et al.
Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin {+/-} taxane-pretreated ovarian cancer patients
Ann. Onc., February 20, 2002; 13(2): 258 - 266.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Montazeri, S. Culine, B. Laguerre, F. Pinguet, F. Lokiec, N. Albin, A. Goupil, R. Deporte-Fety, R. Bugat, P. Canal, et al.
Individual Adaptive Dosing of Topotecan in Ovarian Cancer
Clin. Cancer Res., February 1, 2002; 8(2): 394 - 399.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. L. Clarke-Pearson, L. Van Le, T. Iveson, C. W. Whitney, P. Hanjani, G. Kristensen, J. H. Malfetano, R. A. Beckman, G. A. Ross, S. R. Lane, et al.
Oral Topotecan as Single-Agent Second-Line Chemotherapy in Patients With Advanced Ovarian Cancer
J. Clin. Oncol., October 1, 2001; 19(19): 3967 - 3975.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
S. Guichard, A. Montazeri, E. Chatelut, I. Hennebelle, R. Bugat, and P. Canal
Schedule-dependent Activity of Topotecan in OVCAR-3 Ovarian Carcinoma Xenograft: Pharmacokinetic and Pharmacodynamic Evaluation
Clin. Cancer Res., October 1, 2001; 7(10): 3222 - 3228.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. N. Gordon, J. T. Fleagle, D. Guthrie, D. E. Parkin, M. E. Gore, and A. J. Lacave
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
J. Clin. Oncol., July 15, 2001; 19(14): 3312 - 3322.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Bowman, T. Rye, G. Ross, A. Wheatley, and J. F. Smyth
Effective Dosing of Topotecan With Carboplatin in Relapsed Ovarian Cancer: A Phase I/II Study
J. Clin. Oncol., July 1, 2001; 19(13): 3255 - 3259.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Gore, W. ten Bokkel Huinink, J. Carmichael, A. Gordon, N. Davidson, R. Coleman, M. Spaczynski, J.-F. Heron, G. Bolis, H. Malmstrom, et al.
Clinical Evidence for Topotecan-Paclitaxel Non-Cross-Resistance in Ovarian Cancer
J. Clin. Oncol., April 1, 2001; 19(7): 1893 - 1900.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. E. Royce, P. M. Hoff, P. Dumas, Y. Lassere, J. J. Lee, J. Coyle, M. P. Ducharme, R. De Jager, and R. Pazdur
Phase I and Pharmacokinetic Study of Exatecan Mesylate (DX-8951f): A Novel Camptothecin Analog
J. Clin. Oncol., March 1, 2001; 19(5): 1493 - 1500.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Schilder, J. M. Gallo, M. M. Millenson, M. A. Bookman, L. M. Weiner, A. Rogatko, B. Rogers, K. Padavic-Shallers, M. Boente, N. Rosenblum, et al.
Phase I Trial of Multiple Cycles of High-Dose Carboplatin, Paclitaxel, and Topotecan With Peripheral-Blood Stem-Cell Support as Front-Line Therapy
J. Clin. Oncol., February 15, 2001; 19(4): 1183 - 1194.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Hoskins, E. Eisenhauer, I. Vergote, J. Dubuc-Lissoir, B. Fisher, R. Grimshaw, A. Oza, M. Plante, G. Stuart, and J. Vermorken
Phase II Feasibility Study of Sequential Couplets of Cisplatin/Topotecan Followed by Paclitaxel/Cisplatin as Primary Treatment for Advanced Epithelial Ovarian Cancer: A National Cancer Institute of Canada Clinical Trials Group Study
J. Clin. Oncol., December 15, 2000; 18(24): 4038 - 4044.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Huisman, E. F. Smit, G. Giaccone, and P. E. Postmus
Second-Line Chemotherapy in Relapsing or Refractory Non-Small-Cell Lung Cancer: A Review
J. Clin. Oncol., November 1, 2000; 18(21): 3722 - 3730.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. N. Gordon, C. O. Granai, P. G. Rose, J. Hainsworth, A. Lopez, C. Weissman, R. Rosales, and T. Sharpington
Phase II Study of Liposomal Doxorubicin in Platinum- and Paclitaxel-Refractory Epithelial Ovarian Cancer
J. Clin. Oncol., September 17, 2000; 18(17): 3093 - 3100.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. A. de Jonge, W. J. Loos, H. Gelderblom, A. S. Th. Planting, M. E. L. van der Burg, A. Sparreboom, E. Brouwer, V. van Beurden, M. A. Mantel, E. Doyle, et al.
Phase I Pharmacologic Study of Oral Topotecan and Intravenous Cisplatin: Sequence-Dependent Hematologic Side Effects
J. Clin. Oncol., May 10, 2000; 18(10): 2104 - 2115.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. Piccart, J. A. Green, A. J. Lacave, N. Reed, I. Vergote, P. Benedetti-Panici, A. Bonetti, V. Kristeller-Tome, C. M. Fernandez, D. Curran, et al.
Oxaliplatin or Paclitaxel in Patients With Platinum-Pretreated Advanced Ovarian Cancer: A Randomized Phase II Study of the European Organization for Research and Treatment of Cancer Gynecology Group
J. Clin. Oncol., March 13, 2000; 18(6): 1193 - 1202.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. P. McGuire, J. A. Blessing, M. A. Bookman, S. S. Lentz, and C. J. Dunton
Topotecan Has Substantial Antitumor Activity as First-Line Salvage Therapy in Platinum-Sensitive Epithelial Ovarian Carcinoma: A Gynecologic Oncology Group Study
J. Clin. Oncol., March 1, 2000; 18(5): 1062 - 1062.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. C. White, S. Cheeseman, N. Thatcher, H. Anderson, B. Carrington, S. Hearn, G. Ross, and M. Ranson
Phase II Study of Oral Topotecan in Advanced Non-Small Cell Lung Cancer
Clin. Cancer Res., March 1, 2000; 6(3): 868 - 873.
[Abstract] [Full Text]

Home page
 The OncologistHome page
M. Markman and M. A. Bookman
Second-Line Treatment of Ovarian Cancer
Oncologist, February 1, 2000; 5(1): 26 - 35.
[Abstract] [Full Text]

Home page
 The OncologistHome page
M. A. Bookman
Extending the Platinum-Free Interval in Recurrent Ovarian Cancer: The Role of Topotecan in Second-Line Chemotherapy
Oncologist, April 1, 1999; 4(2): 87 - 94.
[Abstract] [Full Text]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1998 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online